IP Library Granted Patent US 12,146,149
Granted Patent B2
US 12,146,149 · App. 17/047,843 · Granted Nov 19, 2024

Method for adenovirus purification

Inventors: Asa Hagner McWhirter (Uppsala, SE); Anna Akerblom (Uppsala, SE)
Assignee: Cytiva BioProcess R&D AB
C12N15/86C12N7/00C12N15/861C12N2710/10043C12N2710/10051
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,146,149
App. No.
17/047,843
Granted
Nov 19, 2024
Kind
B2
Abstract

The present invention relates to a method for virus purification. The present invention provides downstream processes for purification of adenovirus from cell culture harvest. More closely, it relates to a method for adenovirus purification using a virus capture and a virus polishing step.

Claims (7)

1. A method for adenovirus purification comprising the following steps: a) capturing adenovirus from an adenovirus-containing cell culture harvest on an anion exchanger resin, wherein the anion exchange resin comprises an agarose base matrix modified with a quaternary ammonium strong ion exchange ligand; b) eluting said adenovirus with a shallow conductivity gradient with an increasing salt concentration (mM) of 15-25% over the gradient; c) adding said eluted adenovirus to a shell bead resin comprising a porous, inert shell and a porous core, wherein the core is provided with hydrophobic interaction ligands; and d) eluting said adenovirus from said shell bead resin in the flow through, wherein the adenovirus eluted in step d) comprises less than 1 ng/ml host cell protein (HCP).

2. The method according to claim 1 , wherein the salt is selected from NaCl, KCl and LiCl, or any combinations thereof.

3. The method according to claim 1 , wherein the salt is NaCl and the gradient is increasing 18-20% and the salt concentration is between 0-700 mM.

4. The method according to claim 1 , wherein the anion exchange resin is packed in a column and the shell bead resin is packed in another column, and wherein the adenovirus eluted from the anion exchanger resin is added to the shell bead resin in a volume corresponding to 15-30 column volumes (CV) of the column comprising shell bead resin.

5. The method according to claim 4 , wherein the adenovirus eluted from the anion exchanger resin is added to the shell bead resin in a volume corresponding to 25-30 column volumes (CV) of the column comprising shell bead resin.

6. The method according to claim 1 , wherein the porosity of the core and shell is the same of the shell bead resin.

7. The method according to claim 1 , wherein the porosity of the core and shell is different of the shell bead resin.

Assignments (2)
CHANGE OF NAME Recorded Oct 19, 2020
From: GE HEALTHCARE BIOPROCESS R&D AB
To: CYTIVA BIOPROCESS R&D AB
Reel/Frame 054117/0873 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 15, 2020
From: HAGNER MCWHIRTER, ASA; AKERBLOM, ANNA
To: GE HEALTHCARE BIOPROCESS R&D AB
Reel/Frame 054064/0900 →
Priority Claims (1)
GB 1806736 · Apr 25, 2018 · national
Continuity (1)
Related Publication 20210292788A1 · Sep 23, 2021